XTX Topco Ltd Has $55,000 Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

XTX Topco Ltd lessened its position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 48.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,172 shares of the company’s stock after selling 15,203 shares during the quarter. XTX Topco Ltd’s holdings in Voyager Therapeutics were worth $55,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its stake in Voyager Therapeutics by 53.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 60,462 shares of the company’s stock valued at $204,000 after buying an additional 21,149 shares during the period. Raymond James Financial Inc. bought a new position in shares of Voyager Therapeutics during the fourth quarter worth about $746,000. Northern Trust Corp grew its holdings in shares of Voyager Therapeutics by 3.0% during the fourth quarter. Northern Trust Corp now owns 418,745 shares of the company’s stock worth $2,374,000 after buying an additional 12,374 shares in the last quarter. CWM LLC grew its stake in Voyager Therapeutics by 856.3% in the first quarter. CWM LLC now owns 10,471 shares of the company’s stock valued at $35,000 after purchasing an additional 9,376 shares in the last quarter. Finally, Vestal Point Capital LP grew its stake in Voyager Therapeutics by 151.0% in the fourth quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock valued at $6,974,000 after purchasing an additional 740,000 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Trading Up 0.3%

NASDAQ:VYGR opened at $3.73 on Friday. The stock has a market cap of $206.90 million, a P/E ratio of -2.02 and a beta of 0.90. The stock has a 50 day simple moving average of $3.25 and a 200 day simple moving average of $3.57. Voyager Therapeutics, Inc. has a 1-year low of $2.64 and a 1-year high of $8.27.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%. The firm had revenue of $5.20 million for the quarter, compared to analyst estimates of $9.50 million. As a group, sell-side analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Wedbush decreased their price target on Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Voyager Therapeutics has a consensus rating of “Buy” and a consensus price target of $13.25.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.